Papillary fibroelastomas (PFEs) are rare, benign and generally slow growing tumors of the heart. According to the incidence, they are the third cardiac tumors (after myxoma and lipoma) and represent about 10% of primary intracardiac tumors. Although histologically benign, they cannot be considered as harmless endothelial lesions and may serve as a nidus allowing formation of large superimposed thrombi over a short period of time. Related embolic events are frequent involving adults in their active period of life. PFE-s are usually small (mostly 9-12 mm in diameter) and their recently described more frequent finding is associated with the advancement of diagnostic methods. They can be sessile or pedunculate, with stems 1-3 mm long, mostly solitary, and multiple in less than 10% of cases. PFE occur most commonly on the valves, respectively on the left side of the heart and they are the most common valvular heart tumors. The aortic valve is the primary involved location followed by the anterior mitral leaflet, while PFE can be found rarely on other valves, chordae, and papillary muscles. Approximately 1/2 of patients have symptoms related to PFE (amaurosis fugax, transient ischemic attack, stroke, angina, myocardial infarction, ventricular tachycardia / fibrillation, syncope, sudden death, acute valvular dysfunction). The symptoms are the result of a mechanical effect of the tumor or occur due to the embolisation. Transesophageal echocardiography is the recommended method for diagnosis, with an overall sensitivity of 77%. Symptomatic PFE-s should be surgically resected while the treatment of asymptomatic tumors is less clear. Large, left-sided, pedunculate and mobile tumors that grow fast should be excised to prevent sudden death and embolisation. Small (less then 10 mm in diameter) and non-mobile tumors that do not have the contact with the coronary ostia may be clinically followed-up with serial echocardiography examinations and removed if they increase in size, become mobile or symptomatic. This benign valve tumors usually do not recur. In this study we present our clinical experience with PFE-s and the review of the literature. On our clinical series, we will show interesting morphological variations and unexpected clinical presentation of these (maybe) not so rare and (definitely) not insignificant cardiac tumors.

**KEYWORDS:** heart valves, benign heart tumors.

**Received:** 20th Mar 2013

*Address for correspondence: Klinički bolnički centar Rijeka, Tome Stržiža 3, HR-51000 Rijeka, Croatia.
Phone: +385-51-407-149
Fax: +385-51-218-059
E-mail: alen.ružič1@rt.t-com.hr

**Literature**